Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Total Current Liabilities (2016 - 2025)

Iovance Biotherapeutics has reported Total Current Liabilities over the past 13 years, most recently at $138.4 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $138.4 million for Q4 2025, up 13.09% from a year ago — trailing twelve months through Dec 2025 was $138.4 million (up 13.09% YoY), and the annual figure for FY2025 was $138.4 million, up 13.09%.
  • Total Current Liabilities for Q4 2025 was $138.4 million at Iovance Biotherapeutics, up from $125.8 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for IOVA hit a ceiling of $138.4 million in Q4 2025 and a floor of $83.2 million in Q1 2024.
  • Median Total Current Liabilities over the past 3 years was $116.3 million (2023), compared with a mean of $109.9 million.
  • Biggest five-year swings in Total Current Liabilities: decreased 4.65% in 2024 and later surged 47.44% in 2025.
  • Iovance Biotherapeutics' Total Current Liabilities stood at $110.3 million in 2023, then grew by 10.91% to $122.3 million in 2024, then grew by 13.09% to $138.4 million in 2025.
  • The last three reported values for Total Current Liabilities were $138.4 million (Q4 2025), $125.8 million (Q3 2025), and $129.2 million (Q2 2025) per Business Quant data.